About this trial
The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and muscle capillary blood volume, improves vascular function in the larger conduit vessels, and enhances insulin's metabolic action in humans with Type 2 diabetes. Subjects will be randomized to one of the three groups: exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 16 weeks of intervention.
Eligibility criteria
Qualifiers
Age 21-60
A1C ≤ 8.5%
Never on GLP-1RA (eg: exenatide, liraglutide) or DPP4I ( eg: Sitaglipton)
On stable dose of oral hypoglycemic agents >4 months
Disqualifiers
Taking Insulin
Smoking presently or in the past 6 months
BP >160/90
BMI >35
Trial design
Treatments tested in this trial
- Exercise
- Liraglutide
Treatment groups
Sponsors and collaborators
University of Virginia
Lead sponsor
American Diabetes Association
Collaborator
National Institutes of Health (NIH)
Collaborator